Proactive Investors - Run By Investors For Investors

C4X teams up with PhoreMost to look for potential Parkinson’s treatments

By combining their drug discovery and validation platforms, C4X and PhoreMost hope to find drug targets that can potentially treat Parkinson’s sufferers
old man
There is potential for the pair to look for drugs for other as-yet untreatable diseases

C4X Discovery Holdings plc (LON:C4XD) has teamed up with fellow UK-based biopharma, PhoreMost, to look for treatments for Parkinson’s Disease and other ‘undruggable’ diseases.

The pair will take potentially useful compounds already identified by C4X’s Taxonomy 3 platform and run them through PhoreMost’s SITESEEKER screening platform.

That data can then be exploited by C4X’s Conformetrix drug discovery platform to help produce “commercially attractive small molecule drugs”.

READ: C4X sees significant interest in drug programme

While the initial focus is on Parkinson’s, C4X and PhoreMost believe the complementary nature of the technology platforms means there is potential to extend the collaboration to additional indications in the future.

“As part of our strategy to become the world's most productive drug discovery company, we continually assess cutting edge technologies that add to our current capabilities in target identification and drug design,” said C4X chief executive Clive Dix.

“PhoreMost has one such technology with the potential to both validate targets and provide chemistry starting points for our molecular design platforms.

“This partnership complements C4XD's existing target validation collaborations and enables us to accelerate our portfolio growth whilst decreasing the timelines in drug discovery.”

PhoreMost CEO, Chris Torrance, added: “We are thrilled to be joining forces with C4XD within this neurodegeneration collaboration, a therapeutic area that has a pressing need for new and better targets.”

C4X shares were up 4.6% to 52.8p in early deals on Tuesday.

View full C4XD profile View Profile

C4X Discovery Holdings plc Timeline

Related Articles

cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use